Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609072 · ClinicalTrials.gov registry record
Connect for Cancer Prevention Study (Connect)
A clinical trial of Cancer and General Research Use, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 200,000
- Enrollment target
- 10
- Study locations
NCT04609072 is a study of Cancer and General Research Use that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 200,000 participants, above the 3,166-participant average among 615 other Cancer trials with a reported enrollment target (6217% higher). The trial reports 10 study locations across 10 states.
The verdict
NCT04609072, a study of Cancer and General Research Use, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk. Objective: To study and better understand the causes of cancer and to find new ways to prevent it. Eligibility: The study will include 200,000 adults who get their health care from a partner health care system, are between 30 and 70 years old at enrollment, and have never had cancer. People remain eligible to join if they have or once had non-melanoma skin cancer, or a condition that may raise cancer risk (such as ductal carcinoma in situ, or DCIS). Design: Eligible recruits can sign up for Connect online by creating an account on MyConnect using their email address or phone number. After creating an account, they will complete the informed consent process. All information shared through MyConnect is secure to protect participant privacy. After joining the study, participants will be asked to answer online health surveys a few times a year, donate samples of blood, urine, and saliva every two to three years, and safely share access to their electronic health records with Connect. In the future, participants may donate unused samples that are collected at clinical visits, like tissue, stool, or blood, and may mail in samples collected at home. Participants may also share information from personal health trackers, like wearable devices or apps. This information will help researchers study the health and behavior patterns that may affect cancer risk. It takes time to understand the causes of cancer, so Connect will go on for many years. The longer people participate, the more researchers may lear
Conditions Studied
Study Locations (10)
Colorado
- Kaiser Permanente Colorado - Denver
Georgia
- Kaiser Permanente Georgia - Atlanta
Hawaii
- Kaiser Permanente Hawaii - Honolulu
Illinois
- University of Chicago Medical Center - Chicago
Michigan
- Henry Ford Health Systems - Detroit
Minnesota
- HealthPartners - Minneapolis
Oregon
- Kaiser Permanente Northwest - Portland
South Dakota
- Sanford Health - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2070-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04609072
The ClinicalTrials.gov registry entry for NCT04609072 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,166-participant average among 615 other Cancer trials with a reported enrollment target (6217% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04609072 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Colorado, Georgia, Hawaii.
Frequently Asked Questions
What is clinical trial NCT04609072 about?
NCT04609072 is a clinical study titled "Connect for Cancer Prevention Study (Connect)". Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of pe...
What is the current status of trial NCT04609072?
This trial is currently recruiting. The enrollment target is 200,000 participants. The study started on 2021-07-26. Estimated completion is 2070-12-31.
What conditions does trial NCT04609072 study?
This clinical trial studies the following conditions: Cancer, General Research Use.
Who is sponsoring clinical trial NCT04609072?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04609072 being conducted?
This trial has 10 study locations across Colorado, Georgia, Hawaii, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.